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Calcium-Sensing Receptor 
Antagonist NPS 2143 Restores 
Amyloid Precursor Protein 
Physiological Non-Amyloidogenic 
Processing in Aβ-Exposed Adult 
Human Astrocytes
Anna Chiarini1, Ubaldo Armato  1, Daisong Liu2 & Ilaria Dal Prà1
Physiological non-amyloidogenic processing (NAP) of amyloid precursor holoprotein (hAPP) by 
α-secretases (e.g., ADAM10) extracellularly sheds neurotrophic/neuroprotective soluble (s)APPα 
and precludes amyloid-β peptides (Aβs) production via β-secretase amyloidogenic processing (AP). 
Evidence exists that Aβs interact with calcium-sensing receptors (CaSRs) in human astrocytes and 
neurons, driving the overrelease of toxic Aβ42/Aβ42-os (oligomers), which is completely blocked by CaSR 
antagonist (calcilytic) NPS 2143. Here, we investigated the mechanisms underlying NPS 2143 beneficial 
effects in human astrocytes. Moreover, because Alzheimer’s disease (AD) involves neuroinflammation, 
we examined whether NPS 2143 remained beneficial when both fibrillary (f)Aβ25–35 and a microglial 
cytokine mixture (CMT) were present. Thus, hAPP NAP prevailed over AP in untreated astrocytes, which 
extracellularly shed all synthesized sAPPα while secreting basal Aβ40/42 amounts. Conversely, fAβ25–35 
alone dramatically reduced sAPPα extracellular shedding while driving Aβ42/Aβ42-os oversecretion that 
CMT accelerated but not increased, despite a concurring hAPP overexpression. NPS 2143 promoted 
hAPP and ADAM10 translocation to the plasma membrane, thereby restoring sAPPα extracellular 
shedding and fully suppressing any Aβ42/Aβ42-os oversecretion, but left hAPP expression unaffected. 
Therefore, as anti-AD therapeutics calcilytics support neuronal viability by safeguarding astrocytes 
neurotrophic/neuroprotective sAPPα shedding, suppressing neurons and astrocytes Aβ42/Aβ42-os 
build-up/secretion, and remaining effective even under AD-typical neuroinflammatory conditions.
Alzheimer’s disease (AD) causes dementia in tens of millions of people worldwide1. The typical markers of AD 
are senile plaques, i.e., accumulations of amyloid-β peptides (Aβs) in the neuropil; neurofibrillary tangles (NFTs), 
i.e., insoluble clusters of hyperphosphorylated Tau proteins inside neurons; the loss of synaptic contacts; neuro-
toxicity; increased cell death in neurons and oligodendrocytes; activated astrocytes and microglia; chronic neu-
roinflammation; cerebrovascular damage; and blood-brain barrier dysfunction2–4. These markers are present in 
extended cortical areas up to fifteen years before the onset of any memory or cognition decline2, 5, 6.
Amyloid precursor holoprotein (hAPP)’s pathophysiological relevance in AD is notorious7, 8. Human hAPP 
and its mammalian homologues AP-like protein 1 (APLP1) and 2 (APLP2) are integral transmembrane proteins 
that promote cell adhesion by homo- or hetero-dimerization or functioning as receptors9. Their manifold physi-
ological activities include the modulation of cell survival, axonal growth, synaptogenesis, synaptic plasticity, and 
neuronal excitability7, 8, 10. hAPP is synthesized in the endoplasmic reticulum (ER), post-translationally modified 
by N- and O-linked glycosylation, and transported along the secretory pathway to the cell surface11.
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Importantly, hAPP undergoes proteolysis via two pathways: amyloidogenic processing (AP) and 
non-amyloidogenic processing (NAP). In AP, BACE (β-site APP cleaving enzyme)1/β-secretase, a 
membrane-bound aspartyl protease, cleaves the N-terminus of the hAPP Aβ domain in the trans-Golgi net-
work (TGN) and, following endocytosis, in the endosomal/lysosomal system11–15, thereby releasing (shedding) a 
pro-apoptotic soluble (s)APPβ ectodomain14, 15. The membrane-bound γ-secretase complex, comprising prese-
nilins 1 (PS1) and 2 (PS2), cleaves the C99 or CTFβ (99 amino acid C-terminal fragment) of membrane-bound 
hAPP, producing (i) Aβs and (ii) the hAPP intracellular domain (AICD) peptide, which might play a transcrip-
tional role16–19. Therefore, mutations in the genes encoding hAPP, PS1 or PS2 drive early-onset familial AD 
(EOFAD; <3% cases) by driving the surplus production/release of Aβs, which then cluster as variously sized toxic 
oligomers (Aβ-os) or polymers (fibrils)19. Conversely, the aetiologic factors underlying the prevailing (>95% 
cases) late-onset (sporadic) AD (LOAD) cases are likely manifold, slow-acting, and less defined than those under-
lying EOFAD. Only heterozygous or homozygous apolipoprotein E (APOE) ε4 alleles and TREM-2 mutations, 
chiefly R47H, aid the onset and progression of LOAD20. Therefore, various vascular and metabolic shortcomings 
interact to hinder the brain’s clearance of the Aβs that accumulate in the neuropil2–4, 21. However, even in LOAD, 
neuropil-clogging Aβs drive, via Aβ•CaSR (calcium-sensing receptor) signalling, increased AP of hAPP, causing 
the surplus production/release of Aβ42/Aβ42-os from both astrocytes and neurons. Such Aβs devastatingly spread 
from the hippocampus to a wide range of upper cortical areas22–24.
Under physiological conditions, hAPP NAP typically prevails: hAPP is mostly cleaved between amino acids 
612 and 613 within the Aβ domain by α-secretase, which impedes any Aβ production7, 19. Physiologically, 
ADAM10 (a disintegrin and metalloprotease domain-containing protein 10) is the principal hAPP α-secretase in 
neurons25, which acts mainly at the cell surface and within the TGN26, 27 and sheds the soluble (s)APPα ectodo-
main from hAPP25, 28.
sAPPα acts as a neurotrophic and neuroprotective compound in brain ischaemic, traumatic, and excito-
toxic injuries29, 30. Interestingly, sAPPα levels decrease in the cerebrospinal fluids of AD patients31. This decrease 
implies a partial loss of sAPPα activity, resulting in reduced plasticity, connectivity, and synaptic signalling, all 
of which favour the demise of neurons that occurs in AD10, 31. The ectodomains of both membrane-bound hAPP 
and shed sAPPα play neuroprotective roles in vitro25, 30, 32–37, although the receptor(s) and signalling pathway(s) 
involved remain unclear. Moreover, we know little about the complex mechanisms that modulate hAPP NAP and 
AP balance, particularly in cortical untransformed human neurons and astrocytes; however, hAPP intracellular 
trafficking, γ-secretase38, and α-secretase27, 39 are involved. Undoubtedly, clarification of the mechanisms involved 
would impact our understanding of AD pathophysiology and therapy.
Previously, most studies focused on neurons as the main sites of BACE1/β-secretase expression40, 41 and Aβ 
production in mouse brains3, 42, 43. Activated microglia are the second most investigated brain cell type, as they 
engulf fibrillar and soluble Aβs, promote Aβ clumping inside senile plaques, secrete proinflammatory cytokines, 
and overrelease toxic nitric oxide (NO) and reactive oxygen species (ROS)3, 4, 44. Conversely, astrocytes were 
believed to scavenge, accumulate, proteolyze, and release Aβs, thereby promoting the build-up of glial fibrillary 
acidic protein (GFAP)-rich senile plaques45. However, recent evidence shows that astrocytes also play pivotal 
roles in the onset and progression of human AD, being more numerous than neurons, establishing extended 
inter-astrocyte networks via gap junctions, forming teams with client neurons, wrapping tripartite synapses, shel-
tering neurons from environmental toxins, and exchanging with them physiological and pathological (e.g., Aβs) 
metabolic compounds46–48. Eventually, the benefits of the neuron-sustaining activities of astrocytes vanish when 
the Aβ-clearing activity becomes too intense45–49.
Blasko et al.50 first reported that human astrocytes produce Aβ40 and Aβ42 upon exposure to pairs of micro-
glial proinflammatory cytokines, such as interferon (IFN)-γ plus tumour necrosis factor (TNF)-α or interleukin 
(IL)-1β44. Activated cortical astrocytes from neonatal mice also exhibited elevated levels of hAPP, BACE1 activ-
ity, and Aβ40 secretion when challenged with IFN-γ + TNF-α or sAβ42 or fAβ4251. These findings suggested that 
neuroinflammation might drive Aβ production/release from human and rodent astrocytes, thus increasing the 
Aβ load in the brain. Importantly, cortical untransformed adult human astrocytes synthesize, accumulate, and 
secrete increased amounts of endogenous Aβ42/Aβ42-os when exposed to exogenous fAβ25–35 or sAβ25–3522–24, 52. 
Additionally, exogenous Aβs specifically bind plasma membrane CaSRs and activate their manifold signalling, 
which drives repeated cycles of exogenous Aβs ⇒ endogenous Aβ42 production/secretion in human cortical 
astrocytes and neurons22–24, 53.
CaSRs, which are a family C G-protein-coupled receptors, quickly recognize changes in extracellular Ca2+ 
levels [Ca2+]e, yet also bind other cations such as polyamines, amino glycoside antibiotics, and Aβs22–24, 53, 54. The 
intracellular domains of CaSRs interact with various G-proteins to modulate a complex set of signalling activities, 
including (i) protein kinases (AKT, PKCs, MAPKs); (ii) phospholipases (A2, C, and D); (iii) transcription factors 
(TFs); (iv) second messenger production (e.g., cAMP); and (v) Ca2+ influx via TRPC6-encoded receptor-operated 
channels55, 56. All cells in the central nervous system (CNS) express CaSRs, though expression levels vary by 
region, with particularly high expression in the hippocampus57. In addition, proliferatively quiescent untrans-
formed adult human astrocytes express functional CaSRs more strongly than growing astrocytes independent of 
[Ca2+]e changes58. Aside from regulating general Ca2+ homeostasis55, CaSRs play additional important roles in 
the CNS24, 59.
Altered expression or dysfunction of CaSRs also impacts CNS diseases, such as AD and ischaemia/hypoxia/
stroke, by modulating amyloidogenesis, glial activation, outward K+ channel fluxes, NO and VEGF-A overpro-
duction, and neuronal death22–24, 57, 60–63.
The use of non-tumorigenic cortical adult human astrocytes and postnatal HCN-1A neurons as in vitro 
preclinical models has revealed a novel pathological interaction by which exogenous Aβs bind and activate 
CaSRs22–24. In addition to the transient overexpression of the CaSR, this interaction leads to the surplus produc-
tion, accumulation and secretion of Aβ42-os from both astrocytes and neurons, coupled with increased cell death 
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Figure 1. Changes in human astrocytes’ secreted and intracellular amounts of endogenous Aβ42 and Aβ40. (a) 
Aβ42 peptides secreted amounts increase after an exposure to fAβ25−35 ± CMT, but stay unchanged when NPS 
2143 is also added. Points on the curves are means ± SEM of 3–5 independent experiments;  
fAβ25–35 + CMT ± NPS 2143: one-way ANOVA analysis of the complete data set F = 140.805, P < 0.001. 
Bonferroni t-test: comparisons of each treated group versus 0-h group (controls): *P < 0.05; pair-wise 
comparisons between corresponding treatments ± NPS 2143 at each time point: #P < 0.05. (b) Changes in 
Aβ40 released amounts according to the treatments. Points on the curves are means ± SEM of 3–5 independent 
experiments; fAβ25–35 + CMT ± NPS2143: one-way ANOVA analysis of the complete data set F = 13.871, 
P < 0.001. Bonferroni t-test: comparisons of each treated group versus 0-h group (controls): *P < 0.05. (c) Left 
panel. Typical immunoblot revealing the changes in intracellularly accumulated Aβ42/Aβ42-os versus untreated 
controls according to treatments. LC, loading control. Right panel. Densitometric evaluations of the whole 
sets of intracellular Aβ42 bands at each time point. Points on the curves are means ± SEM of 3 independent 
experiments, with control values normalized as 1.0. One-way ANOVA analysis of the complete data set 
F = 3.933, P < 0.012. Bonferroni t-test: comparisons of each treated group versus 0-h group (controls): *P < 0.05. 
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among the latter. The CaSR agonist NPS R-568 increases Aβ42-os release from human cortical astrocytes, mim-
icking the effect of Aβ25–35•CaSR signalling22–24. Simultaneously, Aβ-os•CaSR signalling in astrocytes induces the 
surplus production/release of NO and VEGF-A58, 61. These findings suggested that various phenylalkylamines, 
acting as allosteric CaSR antagonists (calcilytics; e.g., NPS 89636 and NPS 2143) capable of shifting the CaSR 
response curve to changes in [Ca2+]e54, 64, may be potential AD therapeutics. Calcilytic NPS 2143 suppressed all 
aforementioned neurotoxic effects elicited by exogenous Aβ25–35•CaSR signalling and fully preserved neuronal 
viability22–24.
Given the potential value for AD therapy, in this work, we explored for the first time the mechanisms under-
lying the beneficial effects of NPS 2143 in human astrocytes, particularly the effects of Aβ•CaSR signalling on the 
NAP of hAPP and the modulation of such effects by a calcilytic. Moreover, as AD progression in the human brain 
is coupled with diffuse, chronic neuroinflammation65, we sought to determine whether a calcilytic might still 
antagonize the noxious effects of fAβ25–35•CaSR signalling when a microglial cytokine mixture trio (CMT; i.e., 
IFN-γ, TNF-α, and IL-1β) was also administered58. The results reported herein further strengthen our view22–24 
that calcilytics embody a novel class of anti-AD therapeutics that effectively maintain the physiological shedding 
of neurotrophic and neuroprotective sAPPα by human astrocytes, as well as fully antagonizing all Aβ25–35•CaSR 
signalling-elicited neurotoxic effects, even in the presence of microglial proinflammatory cytokines.
Results
The specific involvement of CaSRs in the following studies was shown by the inhibitory effects of a highly selec-
tive antagonist, NPS 2143, on the NO release and cAMP levels elicited by various treatments (see Supplementary 
Information and Fig. S1). The reversemer peptide Aβ35–25 was always ineffective (not shown).
Calcilytic NPS 2143 suppresses Aβ42/Aβ42-os oversecretion driven by fAβ25–35 ± CMT. Secreted 
and intracellular Aβ42 levels. The amount of endogenous Aβ42/Aβ42-os released from fAβ25–35-exposed human 
astrocytes rose quickly at first and then more slowly. Co-treatment with CMT hastened the secretion of endog-
enous Aβ42/Aβ42-os, which peaked at 48 h (Fig. 1a). However, CMT addition only marginally increased the total 
amount of Aβ42/Aβ42-os secreted over 72 h versus fAβ25–35 alone (Fig. 1d). NPS 2143 treatment fully suppressed 
the surplus secretion of endogenous Aβ42/Aβ42-os caused by fAβ25–35 ± CMT, maintaining the total amount of 
Aβ42/Aβ42-os secreted from 0 h to 72 h at control levels (Fig. 1a,d).
In contrast, fAβ25–35 + CMT treatment transiently decreased intracellular Aβ42/Aβ42-os levels by 24 h (Fig. 1c). 
Moreover, the addition of NPS 2143 along with fAβ25–35 + CMT elicited a progressive decline in intracellular Aβ42/
Aβ42-os levels (Fig. 1c). Thus, both CMT and NPS 2143, either alone or together, hindered the fAβ25–35-driven 
intracellular build-up of Aβ42/Aβ42-os. A previous densitometric analysis of specific immunoblot bands showed 
that between 0 h and 48 h, the total intracellular levels of Aβ42/Aβ42-os more than tripled in fAβ25–35-treated 
astrocytes versus untreated controls. Conversely, NPS 2143 fully suppressed this fAβ25–35-elicited effect at all 
time-points (not shown; details in Armato et al.22).
Intracellular and secreted Aβ40 levels. Adding CMT ± NPS 2143 with Aβ25–35 suppressed any surge in intra-
cellular Aβ40 levels (data not shown). fAβ25–35 + CMT treatment decreased Aβ40 secretion only after 72 h. NPS 
2143 + fAβ25–35 steadily increased Aβ40 secretion. However, adding NPS 2143 + fAβ25–35 + CMT caused a tran-
sient spike in Aβ40 secretion after 24 h (Fig. 1b). Therefore, the pattern of Aβ40 secretion sharply differed from 
that of Aβ42 in adult human astrocytes (cf. Fig. 1a and b). Previously, we observed a significant fAβ25–35-induced 
intracellular build-up of Aβ40, which peaked at 24–48 h and was only marginally affected by NPS 2143 treatment 
for 48 h; conversely, fAβ25–35 alone did not alter the level of Aβ40 secretion versus untreated controls (for details, 
see ref. 22).
Secreted Aβ42/Aβ40 ratios. In the astrocyte-conditioned growth media, Aβ25–35 + CMT increased the secreted 
Aβ42/Aβ40 ratio into the cytotoxic range, similar to Aβ25–35 alone (see for details22) (Fig. 1e). Conversely, add-
ing NPS 2143 maintained the secreted Aβ42/Aβ40 ratios of fAβ25–35 + CMT-exposed astrocytes within the 
non-cytotoxic range observed in the controls (Fig. 1e). Therefore, by suppressing the overrelease of endogenous 
Aβ42/Aβ42-os in the presence of Aβs + CMT, NPS 2143 further highlighted the potential roles of Aβ•CaSR sig-
nalling in AD development.
NPS 2143 rescues the fAβ25–35 ± CMT-induced block in the physiological shedding of 
sAPPα. Several studies have highlighted the key physiological roles hAPP NAP plays through the shedding 
of neurotrophic and neuroprotective sAPPα via α-secretase activity18, 25, 65. Therefore, we investigated how sAPPα 
shedding is altered in human astrocytes exposed to fAβ25–35 ± CMT ± NPS 2143.
(d) Alterations in total 0-to-72-h amounts of secreted Aβ42 according to treatments. Bars are means ± SEM of 5 
independent experiments. One-way ANOVA analysis of the complete data set F = 13.248, P < 0.001. Bonferroni 
t-test: comparisons of each treated group versus 0-h group (controls): *P < 0.05; pair-wise comparisons between 
corresponding treatments ± NPS 2143: #P < 0.05. (e) Changes in secreted Aβ42/Aβ40 ratio values according to 
treatments in the conditioned growth media of astrocytes. Bars are means ± SEM of 3 independent experiments. 
One-way ANOVA analysis of the complete data set F = 73.769, P < 0.001; Bonferroni t-test: comparisons of 
each treated group versus 0-h group (controls): *P < 0.05; pair-wise comparisons between corresponding 
treatments ± NPS 2143 at each time point: #P < 0.05.
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Figure 2. Changes in human astrocytes intracellularly accumulated and extracellularly shed amounts of 
sAPPα according to treatments. (a) Cumulative curves of sAPPα shed into the medium by astrocytes as 
affected by treatments. Points on the curves are means ± SEM of 5 independent experiments. One-way ANOVA 
analysis of each complete data set: fAβ25–35: F = 80.877, P < 0.001; fAβ25–35 + NPS 2143: F = 35.365, P < 0.001; 
fAβ25–35 + CMT: F = 50.882, P < 0.001; fAβ25–35 + CMT + NPS 2143: F = 34.261, P < 0.001. Bonferroni t-test: 
comparisons of each treated group versus 0-h group (controls): *P < 0.05; pair-wise comparisons between 
corresponding treatments ± NPS 2143 at each time point: #P < 0.05. (b) Top. Typical immunoblot revealing 
the changes in intracellularly accumulated sAPPα according to treatments versus controls (0-h). LC, loading 
control. Blots have been cropped to size for clarity. Bottom. Densitometric evaluations of intracellular sAPPα 
bands. Points on the curves are means ± SEM of 3 independent experiments, with 0-h values normalized as 1.0. 
One-way ANOVA analysis of each complete data set: fAβ25–35 ± NPS 2143: F = 280.483, P < 0.001;  
fAβ25–35 + CMT ± NPS2143: F = 134.239, P < 0.001. Bonferroni t-test: comparisons of each treated group 
versus 0-h group (controls): *P < 0.05; pair-wise comparisons between corresponding treatments ± NPS 
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Extracellular and intracellular sAPPα levels. Untreated (control) astrocytes constitutively shed steady amounts 
of sAPPα into the medium (Fig. 2a). However, fAβ25–35 ± CMT steadily and similarly decreased sAPPα shedding, 
while simultaneously inducing the oversecretion of endogenous Aβ42 (cf. Fig. 1a). Remarkably, adding NPS 2143 
to fAβ25–35 ± CMT rescued most of the sAPPα shedding (Fig. 2a).
The cleavage of hAPP by ADAM10 is reported to occur at the plasma membrane, the TGN, and in post-TGN 
vesicles27. Hence, we also investigated the intracellular accumulation/retention of sAPPα (Fig. 2b). Between 
0 h and 72 h, intracellular sAPPα was undetectable in untreated (control) astrocytes. Conversely, fAβ25–35 alone 
induced a delayed but progressive increase in intra-astrocyte sAPPα accumulation, which was mostly abolished 
by NPS 2143. fAβ25–35 + CMT treatment also increased intra-astrocyte sAPPα accumulation, which was almost 
completely abolished by NPS 2143. Despite the ongoing increased extracellular shedding of sAPPα (cf. Fig. 2a), 
modest intracellular sAPPα accumulation was observed by 72 h (1/16 of that evoked by fAβ25–35 alone) due to an 
unknown, Aβ·CaSR signalling-independent mechanism (Fig. 2b).
Total changes in sAPPα levels over 72 h. A summary of the total changes in extracellularly shed (white bars) and 
intracellularly accumulated (black-grey bars) sAPPα levels over 72 h (derived from the areas under the respective 
curves) is shown in Fig. 2c. Unquestionably, fAβ25–35 ± CMT strongly increased intracellular sAPPα retention 
while reducing its extracellular shedding (Fig. 2a) and increased the secretion of Aβ42/Aβ42-os (Fig. 1a). The Aβ42/
sAPPα ratio increased between 3.9- and 4.5-fold versus the control in fAβ25–35 ± CMT-treated astrocyte media, 
indicating a robust enhancement of hAPP AP (Fig. 2d). Conversely, adding NPS 2143 to fAβ25–35 ± CMT-treated 
astrocytes maintained the Aβ42/sAPPα ratio close to control levels (Fig. 2d). Clearly, by antagonizing Aβ·CaSR 
signalling, the calcilytic nearly fully restored the physiological, non-amyloidogenic shedding of neurotrophic 
sAPPα while hindering any Aβ42/Aβ42-os oversecretion from fAβ25–35 ± CMT-treated astrocytes (Figs 2a and 1a).
NPS 2143 drives plasma membrane translocation of hAPP in fAβ25–35 ± CMT-exposed astro-
cytes. hAPP was discretely expressed in total protein lysates of untreated astrocytes (Fig. 3a). Steady-state 
hAPP levels, resulting from ongoing producing and processing activities, did not change following treatment 
with fAβ25–35 alone or with fAβ25–35 + NPS 2143 (Fig. 3a). Conversely, hAPP levels increased following exposure to 
fAβ25–35 + CMT versus fAβ25–35 alone, an effect that was amplified rather than counteracted by NPS 2143 (Fig. 3a).
Recent evidence indicates that promoting the delivery of hAPP to the plasma membrane or inhibiting the 
internalization of hAPP favours hAPP NAP66. Hence, we investigated the distribution of hAPP in cortical adult 
human astrocytes following fAβ25–35 ± CMT ± NPS 2143-treatment. We biotinylated proteins on the astrocyte 
cell surface and then assessed the amount of biotinylated hAPP at the plasma membrane, with the remaining 
non-biotinylated hAPP regarded as “intracellular” hAPP (see Methods for details).
Plasma membrane (i.e., biotinylated) hAPP levels (i) peaked at 48 h with fAβ25–35 alone; (ii) increased from 
24 h to 72 h with NPS 2143 + fAβ25–35; (iii) did not change versus the controls with fAβ25–35 + CMT; and (iv) 
increased strongly and progressively with NPS 2143 + fAβ25–35 + CMT (Fig. 3b).
Simultaneously, intracellular hAPP levels (i) decreased steadily and similarly with fAβ25–35 ± NPS 2143; (ii) 
surged rapidly up to 24 h and then plateaued with fAβ25–35 + CMT; and (iii) after a 24-h delay, peaked at 48 h with 
NPS 2143 + fAβ25–35 + CMT and then began to decrease (Fig. 3c).
Thus, antagonizing Aβ•CaSR signalling intensified hAPP trafficking to the plasma membrane, an effect that 
was remarkably intensified by CMT.
NPS 2143 drives the plasma membrane translocation of ADAM10 in astrocytes, reversing the 
sharp decline induced by fAβ25–35 ± CMT treatment. ADAM10 is the key α-secretase in hAPP phys-
iological NAP19, 25. (Concerning the effects of the various treatments on ADAM17 α-secretase, see Fig. S2 in the 
Supplementary Information). Therefore, we assessed plasma membrane biotinylated and non-biotinylated (intra-
cellular) ADAM10 (55-kDa active form) via immunoblotting (Fig. 4a,b).
Plasma membrane ADAM10. During the first 48 h, the level of plasma membrane biotinylated 55-kDa ADAM10 
decreased rapidly in fAβ25–35 ± CMT-treated astrocytes (Fig. 4a). However, adding NPS 2143 to fAβ25–35 ± CMT 
increased plasma membrane ADAM10 levels up to 72 h.
Intracellular ADAM10. The levels of non-biotinylated (“intracellular”) 55 kDa ADAM10 greatly decreased versus 
the controls in fAβ25–35-treated astrocytes and decreased further when NPS 2143 was added to fAβ25–35 (Fig. 4b). 
Conversely, intracellular ADAM10 increased transiently after approximately 48 h in fAβ25–35 + CMT-exposed astro-
cytes, whereas NPS 2143 + Aβ25–35 + CMT marginally reduced intracellular ADAM10 levels.
2143 at each time point: #P < 0.05. (c) The alterations in total 0-to-72-h amounts of extracellularly shed 
and intracellular sAPPα according to treatments or no treatment (controls). Bars are means ± SEM of 3–5 
independent experiments. One-way ANOVA analysis of the (i) shed sAPPα complete data set: F = 44.056, 
P < 0.001; (ii) intracellular sAPPα complete data set: F = 587.435, P < 0.001. Bonferroni t-test: comparisons of 
each treated group versus untreated group (controls): *P < 0.05; pair-wise comparisons between corresponding 
treatments ± NPS 2143 of both intracellular and shed values, respectively: #P < 0.05. (d) Changes in secreted 
Aβ42/sAPPα ratio values according to treatments or no treatment (controls). Bars are means ± SEM of 5 
separate experiments. One-way ANOVA analysis of the complete data set F = 22.123, P < 0.001. Bonferroni 
t-test: comparisons of each treated group versus 0-h (controls): *P < 0.05; pair-wise comparisons between 
corresponding treated group versus added NPS 2143 group: #P < 0.05.
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Figure 3. Holo-APP expression and distribution in human untreated and treated astrocytes. (a) Left panel. 
Representative immunoblots showing the changes in holo-APP expression according to experimental 
treatments versus untreated controls in total astrocytes lysates. LC, loading control. In all cases blots have been 
cropped to size for clarity. Right panel. Densitometric evaluations of holo-APP bands for each treatment and 
time point. Points on the curves are means ± SEM of 3 independent experiments, with 0-h values normalized 
as 1.0. One-way ANOVA analysis of the complete data set: F = 8.889, P < 0.001; Bonferroni t-test comparisons 
of each treated group versus 0-h (controls): *P < 0.05. (b) Left panel. Typical immunoblots showing alterations 
in plasma membrane hAPP levels (details in Methods) according to experimental treatments versus untreated 
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NPS 2143 ± CMT treatment increased the total ADAM10 specific activity in fAβ25–35-exposed 
human astrocytes. Based on the above results, we next assessed the specific activity of ADAM10 in 
total protein lysates (Fig. 5a,b), which (i) increased slightly with fAβ25–35 but substantially after 24 h with NPS 
2143 + fAβ25–35; (ii) immediately increased and then remained steadily elevated with fAβ25–35 + CMT (cf. Fig. 5a); 
and (iii) surged rapidly with the addition of NPS 2143 to fAβ25–35 + CMT (Fig. 5b).
Therefore, fAβ25–35 alone decreased both plasma membrane and intracellular ADAM10 levels. Despite the 
presence of Aβ25–35 ± CMT, NPS 2143 increased the amount of active ADAM10 at the plasma membrane, i.e., 
where greater hAPP translocation was also occurring (cf. Fig. 2b). These NPS 2143-driven events restored neu-
rotrophic sAPPα shedding. Additionally, although it did not hinder the NPS 2143-driven plasma membrane 
translocation of ADAM10, CMT strongly attenuated – through an undefined mechanism – the sharp decline in 
intracellular ADAM10 levels elicited by fAβ25–35 ± NPS 2143.
Discussion
Currently, scant information is available about the mechanisms modulating hAPP proteolysis in cortical untrans-
formed human neural cells. Our previous findings revealed that Aβ•CaSR signalling promotes the AP of hAPP, 
eliciting substantial increases in endogenous Aβ42 accumulation and secretion from adult human astrocytes and 
postnatal neurons22–24. Our present results show for the first time that a highly selective CaSR antagonist (calci-
lytic) rescues the physiological NAP of hAPP, maintaining neurotrophic and neuroprotective sAPPα shedding 
while fully suppressing pathological AP in Aβ-exposed human astrocytes and neurons, even in the presence of 
microglial CMT (Fig. 6). Although our results were obtained only in astrocytes, we previously demonstrated that 
the effects of Aβ•CaSR signalling and its antagonism by a calcilytic on Aβ42 metabolism are very similar in human 
neurons and astrocytes22–24. Hence, an extension of the present findings to neurons is feasible until experimentally 
proven. The concurrent suppression of NO overproduction and adenylate cyclase inhibition (Fig. S1) strengthens 
the view that NPS 2143 specifically antagonized Aβ•CaSR signalling in astrocytes.
Therefore, the present results prove for the first time that a calcilytic agent can effectively correct the balance 
of hAPP processing altered by Aβ•CaSR-signalling-mediated mechanisms in cortical human astrocytes (and 
likely neurons) (Fig. 6). The calcilytic rescues the α-secretase-mediated extracellular shedding of neurotrophic 
and neuroprotective sAPPα at the expense of the BACE1/β-secretase-mediated neurotoxic Aβ42 overrelease. The 
former would safeguard neuronal trophism, viability, and synaptic connections. The latter is inherently dangerous 
because overproduced and oversecreted soluble Aβ42/Aβ42-os and their insoluble fibrillar derivatives are endowed 
with a pernicious self-propagating potential. These peptides can react with CaSRs in adjacent and farther neurons 
and astrocytes, triggering self-spreading and self-perpetuating vicious waves of Aβ•CaSR signalling, and their 
consequent accumulation releases further Aβ42/Aβ42-os surpluses, which likely sustain LOAD progression22–24. 
Most remarkably, calcilytics can break such vicious cycles and hence stop Aβ42 oversecretion and intra-brain dif-
fusion, thus safeguarding neuronal viability and function22–24. In addition, the calcilytic NPS 2143 elicits a robust 
downregulation of total CaSR levels in astrocytes, thereby inducing a lasting cell desensitization to exogenous 
Aβs•CaSR-driven noxious effects22.
Regarding the mechanisms of calcilytics, NPS 2143 notably (i) drives a substantial translocation of hAPP, as 
well as both the precursor (85 kDa; not shown) and active (55 kDa) forms of ADAM10 α-secretase, to the astro-
cyte plasma membrane; (ii) greatly increases the total ADAM10 α-secretase specific activity, particularly in the 
presence of CMT; (iii) maintains the intracellular levels of active ADAM10 (55 kDa) at or above basal values; and 
(iv) restores neurotrophic and neuroprotective sAPPα extracellular shedding close to untreated control levels 
while hindering the intracellular accumulation of sAPPα. Consequently, by concomitantly also suppressing any 
surplus Aβ42 release, NPS 2143 maintains the secreted Aβ42/sAPPα and Aβ42/Aβ40 ratios near controls levels.
As with other type-I transmembrane proteins, hAPP is synthesized in the endoplasmic reticulum (ER). Then, 
hAPP undergoes maturation (glycosylation) while migrating to the Golgi/TGN compartment, where it is mainly 
found in neurons66. Finally, hAPP reaches the plasma membrane via the constitutive secretory pathway, where it 
is inserted to be cleaved by ADAM10 (mainly) α-secretase, shedding the sAPPα ectodomain, which also occurs 
in a post-Golgi compartment67. In addition, through the recognition of its YENPTY motif and clathrin-coated 
pits, hAPP can be quickly endocytosed from the plasma membrane and trafficked back to the membrane, deliv-
ered through endosomes to the lysosomal system for proteolysis66 or alternatively cleaved by BACE1/β-secretase, 
shedding Aβs (the amyloidogenic pathway), particularly if retained in acidic late endosomes, the TGN or ER67. 
Thus, favouring the plasma membrane trafficking or retention of hAPP blocks Aβ production while enhancing 
controls. In all cases blots have been cropped to size for clarity. Right panel. Densitometric evaluation of holo-
APP specific bands for each treatment and time point. Points on the curves are means ± SEM of 3 independent 
experiments, with 0-h values normalized as 1.0. One-way ANOVA analysis of (i) fAβ25–35 ± NPS 2143 data 
set: F = 14.520, P < 0.001; (ii) fAβ25–35 + CMT ± NPS 2143 data set: F = 240.620, P < 0.001; Bonferroni 
t-test: comparisons of each treated group versus 0-h (controls): *P < 0.05; pair-wise comparisons between 
corresponding treatments ± NPS 2143 at each time point: #P < 0.05. (c) Left panel. Characteristic immunoblots 
showing the intracellular holo-APP’s changes versus untreated (0-h) controls according to treatments. LC, 
loading control. In all cases blots have been cropped to size for clarity. Right panel. Densitometric evaluations 
of specific holo-APP bands for each treatment and time point. Points on the curves are means ± SEM of 3 
separate experiments, with 0-h values normalized as 1.0. One-way ANOVA analysis of: (i) fAβ25–35 ± NPS 
2143 data set: F = 9.800, P < 0.001; (ii) fAβ25–35 + CMT ± NPS 2143 data set: F = 10.710, P < 0.001; Bonferroni 
t-test: comparisons of each treated group versus 0-h (controls): *P < 0.05; pair-wise comparisons between 
corresponding treatments ± NPS 2143 at each time point: #P < 0.05.
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sAPPα extracellular shedding via ADAM10 cleavage. hAPP trafficking is regulated by factors that promote Aβ 
generation, such as the SNX family (SNX17 and SNX33), dynamin I, and the RAB GTPase family (RAB1B, RAB6, 
RAB8, and RAB11)68. In addition, factors that regulating α−, β−, and γ-secretase trafficking are able to alter 
hAPP processing and, hence, impact the production of sAPPα or Aβs68. Further investigations will clarify the 
roles played by such factors in human astrocytes.
The activation of a number of cell surface receptors, e.g., muscarinic acetylcholine receptors, platelet-derived 
growth factor (PDGF) receptors, serotonin/5-hydroxytryptamine (5-HT4) receptors, and metabotropic glutamate 
receptors, reportedly exerts differential effects on hAPP AP or NAP69. Our findings add CaSRs to this group 
of receptors. These receptors activate various signalling pathways that regulate extracellular Aβ secretion and 
sAPPα shedding via changes in cytosolic [Ca2+]i, cAMP, inositol 1,4,5-triphosphate, small Rac GTPases, and 
in the activity of a number of protein kinases, including PKA, PKC, mitogen activated protein kinase kinase 
Figure 4. Changes in ADAM10 protein expression and subcellular distribution in human astrocytes. (a) 
Top. Typical immunoblots revealing changes in cell surface biotinylated ADAM10 levels (details in Methods) 
according to experimental treatments versus untreated controls. Blots have been cropped to size for clarity. 
Bottom. Densitometric evaluations of specific ADAM10 bands for each treatment and time point. Points in the 
curves are means ± SEM of 3 independent experiments, with 0-h (controls) values normalized as 1.0. One-way 
ANOVA analysis of (i) fAβ25–35 ± NPS2143 data set: F = 73.625, P < 0.001; (ii) fAβ25–35 + CMT ± NPS2143 
data set: F = 55.591, P < 0.001; Bonferroni t-test: comparisons of each treated group versus 0-h group (controls): 
*P < 0.05; pair-wise comparisons between corresponding treatments ± NPS 2143 at each time point: #P < 0.05. 
(b) Top. Characteristic immunoblots exposing changes in the levels of non-biotinylated intracellular ADAM10 
according to the specific treatments versus untreated controls. In all cases blots have been cropped to size for 
clarity. Bottom. Densitometric evaluation of specific ADAM10 bands for each treatment and time point. Points 
in the curves are means ± SEM of 3 independent experiments, with 0-h values normalized as 1.0. One-way 
ANOVA analysis of (i) fAβ25–35 ± NPS2143 data set: F = 34.818, P < 0.001; (ii) fAβ25–35 + CMT ± NPS2143 data 
set: F = 10.938, P < 0.001; Bonferroni t-test: comparisons of each treated group versus 0-h (controls): *P < 0.05; 
pair-wise comparisons between corresponding treatments ± NPS 2143 at each time point: #P < 0.05.
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(MAPKK), extracellular signal-regulated kinase (ERK), phosphatidylinositol–3-kinase (PI3K), and Src tyrosine 
kinase69. Reduced cholesterol levels also heighten ADAM10 activity and hinder hAPP endocytosis, thus enhanc-
ing sAPPα shedding from cultured cells69. Similar effects can be obtained via ADAM10 overexpression70, phar-
macological muscarinic activation32 or phorbol myristate acetate treatment in hAPP-transfected CHO cells27. 
Conversely, the AP of hAPP was favoured at the expense of sAPPα extracellular shedding following overexpres-
sion of BACE1/β-secretase40 or the Swedish mutant form of hAPP (SweAPP), which is linked to a familial EOFAD 
and is more effectively cleaved by BACE1/β-secretase within the TGN69. In addition, knocking down ADAM1025 
and expressing a dominant-negative ADAM10 mutant in mice70 both increased hAPP AP.
ADAM family members belong to the metzincin superfamily and are typically synthesized as inactive pre-
cursors (zymogens)71. The proteolytic removal of a conserved cysteine switch in the prodomain is necessary to 
activate these zymogens71. Our findings indicate that cleavage by proprotein convertases (e.g., furin and PC7 
in HEK293 cells72) into the 55-kDa ADAM10 active form occurs at the cell surface of human astrocytes rather 
than in late compartments of the secretory pathway. However, the complex mechanisms modulating α-secretase 
cleavage activity are not fully elucidated. ADAM10 is not the sole constitutive α-secretase in neurons25, 73. The 
present findings indicate that antagonizing Aβ·CaSR signalling with a calcilytic agent, in the absence but more 
effectively in the presence of CMT, increases the regulated ADAM10 α-secretase specific activity in adult human 
astrocytes. Treatment with NPS 2143 drives the plasma membrane translocation of both ADAM10 and hAPP 
in fAβ25–35 + CMT-exposed astrocytes. This finding reveals that Aβ·CaSR signalling alone restrains the vesicular 
transport of hAPP and ADAM10 to the plasma membrane, while raising hAPP intracellular levels and AP.
Although it increased ADAM10 α-secretase specific activity, CMT addition had little to no impact on daily 
and cumulative (i.e., over 72 h) extracellular sAPPα secretion. Only NPS 2143 addition restored sAPPα secretion 
to the levels of untreated astrocytes, showing the importance of blocking Aβ•CaSR signalling is in restoring hAPP 
NAP. Regarding the intracellular storage of sAPPα, which did not occur in the untreated astrocytes, CMT addi-
tion altered the kinetics but not the total amount stored in fAβ25–35-exposed astrocytes. As expected, NPS 2143 
reduced most but not all) of the sAPPα storage caused by fAβ25–35 treatment, even in the presence of CMT. The 
reasons why these minor sAPPα fractions were retained regardless of NPS 2143 and CMT treatment are not cur-
rently understood. Intracellular sAPPα accumulation has also been observed in other cellular models, including 
cultured human thyroid cells50.
Increased cleavage of hAPP by α-secretase was previously suggested as a therapeutic approach to AD32. Our 
present results strengthen the role of calcilytics as prospective drugs for AD therapy (Fig. 6). In this regard, calci-
lytics benefits largely overcome the mild hyperparathyroidism they induce in humans, given that AD “inexorably 
Figure 5. ADAM10 specific enzymatic activity alterations in human astrocyte protein lysates. (a) Changes in 
ADAM10 specific activity after an exposure to fAβ25–35 ± NPS 2143. (b) Alterations in ADAM10 specific activity 
increases after treatment with fAβ25–35 + CMT ± NPS 2143. The specific activities in A and B were assayed as 
described in the Methods section. Points on the curves are means ± SEM of 3 independent experiments with 0-h 
values normalized as 1.0. One-way ANOVA analysis of: (i) fAβ25–35 ± NPS2143 data set: F = 7.923, P < 0.001; (ii) 
fAβ25–35 + CMT ± NPS 2143 data set: F = 74.248, P < 0.001; Bonferroni t-test: comparisons of each treated group 
versus 0-h (controls):*P < 0.05; pair-wise comparisons of corresponding treatments ± NPS 2143 at each time 
point: #P < 0.05.
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kills the patient cognitively several years before his/her actual physical demise”22–24. Therefore, the negative conse-
quences of calcilytics should prove negligible if clinical trials prove that they can halt AD development.
Methods
Cell cultures. Untransformed human adult astrocytes were isolated from anonymized surgical fragments 
of normal adult human temporal cortex (brain trauma leftovers) provided by several Neurosurgery Units after 
obtaining written informed consent from all the patients and/or their next-of-kin. Experimental use of isolated 
astrocytes was approved by the Ethical Committee of Verona University-Hospital Integrated Company. All 
human cells experiments were performed in accordance with the relevant guidelines and regulations of Verona 
University-Hospital Integrated Company. Cultures of astrocytes were set up, as previously described22, in a 
medium consisting of 89% (v/v) of a 1:1 mixture of DMEM and F-12 medium (Life Technologies Italia, Monza, 
Italy), 10% (v/v) heat-inactivated (at 56 °C for 30 min) foetal bovine serum (FBS; Life Technologies Italia) and 1% 
(v/v) of a penicillin–streptomycin solution (Lonza Milano, Italy). When the primary cultures reached 70% con-
fluence (4 weeks), the cells were detached with 0.25% (w/v) trypsin and 0.02% (w/v) EDTA (Lonza) in Hanks BSS, 
split 1:4 and planted in new flasks. After the third subculture a homogeneous population of astrocytes obtained. 
In these pure cultures, the cells only expressed astrocyte-specific markers such as glial fibrillary acid protein 
(GFAP) and glutamine synthase (GS). None of the cells expressed neuronal (enolase), oligodendrocytes (galac-
tocerebroside), microglia (CD-68), or endothelial cells (factor VIII) markers. These astrocytes proliferated quite 
slowly in serum-enriched DMEM (Life Technologies Italia) medium and were by now phenotypically “locked-in”.
Aβ peptides. Aβ25–35 (Bachem), a known Aβ1–42 proxy22, was dissolved at 1.5 mM in PBS. Fibrillogenesis by 
Aβ25–35 was checked via thioflavin-T tests before experimental use. The reversemer peptide Aβ35–25 (Bachem) was 
dissolved in the same way as Aβ25–35, but did not form fibrils and when given to the cultures was totally ineffective 
(not shown).
Experimental protocol. Since astrocytes do not actively divide in the adult human brain, we employed 
them once they had reached mitotic quiescence. At experimental “0 h”, culture flasks served partly as untreated 
controls receiving a change of fresh medium and partly received fresh medium with 20 µM of either fibrillar (f)
Aβ25–35 or reversemer Aβ35–25 added. This dose of the fAβs had been found to be ideal in previous studies22–24. 
Part of the treated cultures received 20 µM of fAβ25–35 once (at 0 h) plus a cytokine mixture trio (CMT), that is 
IL-1β (20 ng mL−1), TNF-α (20 ng mL−1), and IFN-γ (70 ng mL−1) (all from PeproTech, London, England). A 
Figure 6. Mechanisms synopsis. Cartoon illustrating the concept that CaSR-dependent signalling can deeply 
affect the balance between hAPP NAP and AP and hence play a role in the promotion or prevention of AD 
development. Left panel. The main mechanisms by which Aβ25–35 alone (top) or +CMT (bottom) alters the 
hAPP physiological NAP in favour of AP. Right panel. The main mechanisms by which calcilytic NPS 2143 
restores the hAPP NAP while hindering the AP in Aβ25–35-exposed adult human astrocytes either in absence 
(top) or in the presence of CMT (bottom). The emojis indicate what most likely happens to the neurons exposed 
to the various agents (human astrocytes survive). See the text for further details.
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second and a third CMT bolus was added at 24-h and 48-h. The CaSR allosteric antagonist (calcilytic) NPS 2143 
HCl (2-chloro-6-[(2 R)–3-1,1-dimethyl-2-(2-naphtyl) -ethylamino-2-hydroxy-propoxy]-benzonitrile HCl; 
Tocris Bioscience, UK)54 was dissolved in DMSO and next diluted in the growth medium at a final concentration 
of 100 nM. At experimental “0-h”, “24-h”, and “48-h” part of the astrocyte cultures were exposed for 30 min to 
NPS 2143 dissolved in fresh medium. Next, the NPS 2143-containing medium was removed and fresh (at 0.5-h) 
medium or the previously astrocyte-conditioned (at 24.5 and 48.5-h) media were added again to the cultures. 
Cultures and cell-conditioned media were sampled at 24 hourly intervals. Phosphoramidon (10 μM; Sigma), an 
inhibitor of thermolysin and other proteases, was added to the media at “0-h” experimental time.
Western immunoblotting (WB). At selected time points, control and treated astrocytes were scraped 
into cold PBS, sedimented at 200 × g for 10 min, and homogenized in T–PER™ tissue protein extraction reagent 
(Thermo Scientific, Rockford, USA) containing complete EDTA–free protease inhibitor cocktail (Roche, Milan). 
Equal amounts (10–30 µg) of protein from the samples were loaded on NuPAGE Novex 4–12% Bis–Tris poly-
acrylamide gel (Life Technologies Italia) and next blotted onto nitrocellulose membranes (0.2 µm) by means of 
iBlotTM Dry Blotting System (Life Technologies Italia). The membranes were probed with: (i) rabbit polyclonal 
anti-Amyloid Precursor Protein (APP), C-Terminal (751–770) diluted 1:2000 (Calbiochem; Merck, Darmastadt, 
Germany); (ii) mouse monoclonal 2B3 antibody anti-sAPPα human C-terminal peptide (IBL International 
GmbH, Hamburg, Germany), diluted at 2.0 µg mL−1; (iii) mouse monoclonal antibody anti-ADAM10 (A3, Santa 
Cruz Biotechnology, Germany) used at 1.0 µg mL−1; (iv) mouse monoclonal antibody anti-Aβ42 (8G7, Acris 
Antibodies GmbH, Germany) used at 1.0 µg mL−1; and (v) goat polyclonal antibody anti-lamin B (Santa Cruz 
Biotechnology) which served to assess loading controls used at 1.0 µg mL−1. The integrated intensities of the 
bands specific for each protein of interest were assessed using the Sigmagel™ software package (Jandel Corp., 
Erkrath, Germany).
Biotinylation and isolation of astrocytes’ plasmalemmal proteins. The PierceTM Cell Surface 
Protein Isolation Kit (Thermo Scientific) served to biotinylate and isolate cell surface proteins. According to 
the supplier’s procedure the cell culture media were removed and astrocytes were washed twice with ice-cold 
PBS followed by incubation with 0.25 mg mL−1 Sulfo-NHS-SS-Biotin in ice-cold PBS on a rocking platform for 
30 minutes at 4 °C. The biotinylation reaction was quenched by adding 500 μl of the provided Quenching Solution 
(Pierce). Astrocytes were harvested by gentle scraping and pelleted by centrifugation at 500 × g for 5 minutes at 
4 °C. After washing with TBS astrocyte pellets were lysed using the provided Lysis Buffer (Pierce) containing a 
protease inhibitor cocktail (Roche) for 30 minutes on ice with intermittent vortexing. To get rid of cell remnants, 
the lysates were centrifuged at 10,000 × g for 2 minutes at 4 °C. To purify biotinylated proteins on Immobilized 
NeutrAvidin Gel, the clarified supernatant was incubated for 1-h at room temperature (RT) to allow the bioti-
nylated proteins to bind to the NeutrAvidin Gel. The unbound proteins, representing the intracellular fraction, 
were collected by centrifugation of the column at 1,000 × g for 2 minutes. Any remaining unbound proteins were 
removed by washing thrice with Wash Buffer (Pierce). Finally, the biotinylated surface proteins were eluted from 
the biotin-NeutrAvidin Gel by incubation with 400 µL of the SDS-PAGE Sample Buffer containing 50 nM DTT 
for 1-h at RT in the end-over-end tumbler, and were collected by column centrifugation at 1,000 × g for 2 minutes.
Assays of α-secretases specific activities. The ADAM10 and ADAM17 enzymatic activities were 
assayed by means of fluorescent methods using EnSensTM ADAM10 and EnSensTM ADAM17 activity detection 
kits (Enzium, Inc., Philadelphia, USA) in the cell lysates. Despite the highly-overlapping substrate specificities 
of ADAM10 and ADAM17, EnSensTM substrates are able to differentiate between the two enzymes. Astrocytes’ 
lysates (20 μg) were incubated with the fluorogenic EnSensTM ADAM10 and EnSensTM ADAM17 substrates, 
respectively for 1-h at RT, protected from light according to the supplier’s protocol. The fluorescence was recorded 
at excitation and emission wavelengths of 625–635 nm and 655–665 nm, respectively. The results were expressed 
as specific activity (means ± SEMs of ΔF µg−1 protein pertaining to each experimental group).
Enzyme-linked immunoassays (ELISAs) of Aβ42, Aβ40, and sAPPα  released into in 
cell-conditioned growth media. Quantifications of Aβ42, and Aβ40 and sAPPα were carried out by 
means of specific Aβ42, and Aβ40 Human/Rat High-Sensitive ELISA Kits (both from Wako, Japan) as previously 
described22 and by means of specific Human sAPPα High-Sensitive ELISA Kit (from IBL International). Briefly, 
the astrocytes conditioned media samples were added with a protease inhibitor cocktail (Roche) and centrifuged 
for 10 minutes at 13,000 rpm to remove any cellular debris. Supernatants were tested in triplicate according to the 
manufacturer protocol.
Statistical analysis. The data were analyzed using Sigma Stat 3.5™ Advisory Statistics for Scientists (Systat 
Software). For immunoblotting, bands’ densitometric data were normalized to matching loading control (lamin 
B1) bands and next analyzed by one–way ANOVA. When the ANOVA’s upshot was significant (P < 0.05), 
Bonferroni t-test, was used for all pairwise comparisons and multiple comparisons versus 0-h (untreated) control 
values. Null hypotheses were rejected when P > 0.05.
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